Edwards Lifesciences Corporation $EW Stock Holdings Decreased by Wendell David Associates Inc.

Wendell David Associates Inc. cut its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 40.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,620 shares of the medical research company’s stock after selling 7,275 shares during the period. Wendell David Associates Inc.’s holdings in Edwards Lifesciences were worth $831,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $67,832,000. Citizens Business Bank boosted its stake in Edwards Lifesciences by 4.7% during the 2nd quarter. Citizens Business Bank now owns 29,958 shares of the medical research company’s stock valued at $2,343,000 after purchasing an additional 1,354 shares during the period. Arista Wealth Management LLC acquired a new position in Edwards Lifesciences during the 2nd quarter valued at about $229,000. Private Trust Co. NA boosted its stake in Edwards Lifesciences by 9.6% during the 2nd quarter. Private Trust Co. NA now owns 4,346 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 380 shares during the period. Finally, Smithbridge Asset Management Inc. DE boosted its stake in Edwards Lifesciences by 6.9% during the 2nd quarter. Smithbridge Asset Management Inc. DE now owns 15,255 shares of the medical research company’s stock valued at $1,193,000 after purchasing an additional 989 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 2.5%

EW stock opened at $74.50 on Friday. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The company has a market capitalization of $43.74 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 3.58 and a beta of 1.05. The firm’s 50-day moving average is $77.54 and its two-hundred day moving average is $76.19. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Wells Fargo & Company boosted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. The Goldman Sachs Group reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.